Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances

Lantern Pharma Inc.

Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.
LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.
LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.
withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.

Period: the fiscal year and fourth quarter ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.